Spike glycoprotein, S glycoprotein N-terminal domain, S-NTD, 4A8

SARS-CoV-2

CPC514C pdf (datasheet)

1.0 mg

Please Inquire

1.0 mg/ml, lot specific

New catalog number RVV00201

Recombinant Human anti-SARS-CoV-2 Spike Protein N-terminal domain, Clone 4A8, is expressed in CHO cell line. Original 4A8 was a human isolate monoclonal antibody that targets the N-terminal domain (NTD) of the SARS-CoV-2 S protein and exhibits high neutralization potency against SARS-CoV-2 although it does not directly inhibit the interaction between RBD and ACE2. Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is an enveloped, positive-sense, single-stranded RNA virus that causes coronavirus disease 2019 (COVID-19). The structural proteins of SARS-CoV-2 include the envelope protein (E), spike or surface glycoprotein (S), membrane protein (M) and the nucleocapsid protein (N). Spike glycoprotein is cleaved into the following 3 chains, Spike protein S1, Spike protein S2, Spike protein S2'. Spike protein S1 attaches the virion to the cell membrane by interacting with host receptor, initiating the infection. Binding to human ACE2 receptor and internalization of the virus into the endosomes of the host cell induces conformational changes in the Spike glycoprotein. Surface glycoprotein is an important target for vaccine development, antibody therapies and diagnostic antigen-based tests.

S

Spike glycoprotein

P0DTC2

CPC514

>95% as determined by SDS-PAGE

Recognizes SARS-CoV-2 Spike-NTD protein

Human

Original derived from a convalescent SARS-CoV-2 patient

IgG1

4A8

Sterile-filtered 100 mM Pro-Ac, 20 mM Arg, pH 5.0

Note formulation change.

Protein A/G affinity chromatography from cell culture supernatant

ELISA, Functional assay, Neutralizing , WB

ELISA: suggested dilution 1:5,000 - 1:10,000
Western blot: suggested dilution 1:1,000 - 1:2,000

Stable at 2-8°C for 1 week or for up to 1 year at -20°C to -80°C. It is recommended to prepare working aliquots of undiluted product and store -20°C to -80°C.